Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.66 |
| ▸ | DDX3X | O00571 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | F2R | P25116 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11426024 | 0.86 | ALDH1A1 (0.62) | ALDH1A1DDX3XSMN1; SMN2LMNAMAPT | |
| SCHEMBL18789769 | 0.83 | ALDH1A1 (0.58) | ALDH1A1DDX3XSMN1; SMN2LMNAMAPT | |
| SCHEMBL16444456 | 0.82 | ALDH1A1 (0.57) | ALDH1A1DDX3XSMN1; SMN2LMNAMAPT | |
| SCHEMBL11420255 | 0.82 | DDX3X (0.65) | ALDH1A1DDX3XSMN1; SMN2LMNAMAPT | |
| SCHEMBL7781791 | 0.81 | ALDH1A1 (0.60) | ALDH1A1DDX3XSMN1; SMN2LMNAKMT2A | |
| SCHEMBL16646786 | 0.81 | ALDH1A1 (0.55) | ALDH1A1DDX3XSMN1; SMN2HDAC3HDAC4 | |
| SCHEMBL20194153 | 0.81 | ALDH1A1 (0.55) | ALDH1A1DDX3XSMN1; SMN2HDAC3HDAC4 | |
| SCHEMBL11876425 | 0.81 | HSD17B10 (0.72) | ALDH1A1DDX3XSMN1; SMN2MAPTL3MBTL1 | |
| SCHEMBL3078788 | 0.81 | KMT2A (0.56) | ALDH1A1SMN1; SMN2LMNAMAPTKMT2A | |
| SCHEMBL6251216 | 0.81 | RXRA (0.50) | ALDH1A1SMN1; SMN2LMNAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11643396-B2 | BRD4-kinase inhibitors as cancer therapeutics | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20200407328-A1 | BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2020-12-31 | — | — | US | disclosed |
| US-10738016-B2 | BRD4-kinase inhibitors as cancer therapeutics | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190055203-A1 | POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2019-02-21 | — | — | US | disclosed |
| US-20170226065-A1 | POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2017-08-10 | — | — | US | disclosed |
| WO-2017066428-A1 | BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8586614-B2 | Urea glucokinase activators | NOVO NORDISK A/S (DK) | 2013-11-19 | — | — | US | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| CN-101263131-B | Urea glucokinase activators | TRANSTECH PHARMA INC | 2013-04-24 | — | — | CN | disclosed |
| US-20070287195-A1 | Carohydrate-Ligand Conjugates and Their Application for the Analysis of Carbohydrate-Protein Interaction | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2007-12-13 | — | — | US | disclosed |
| WO-2007006814-A1 | UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | WO | disclosed |
| US-20070015759-A1 | Metasubstituted thiazolidinones, their manufacture and use as a drug | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-18 | — | — | US | disclosed |
| US-20070015759-A1 | Metasubstituted thiazolidinones, their manufacture and use as a drug | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-18 | — | — | US | disclosed |
| EP-1477484-A1 | Oxonol dye compound, optical information recording medium using the same, and optical information | FUJI PHOTO FILM CO., LTD. (JP) | 2004-11-17 | — | — | EP | disclosed |
| EP-1253148-A2 | Oxonol dye compound, optical information recording medium using the same, and optical information | FUJI PHOTO FILM CO., LTD. (JP) | 2002-10-30 | — | — | EP | disclosed |
| US-4552699-A | Process for the preparation of 3-acylaminoanilines | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-11-12 | — | — | US | disclosed |
| EP-0159291-A1 | Ink composition for the ink-jet printing process | CIBA-GEIGY AG (CH) | 1985-10-23 | — | — | EP | disclosed |
| US-4118232-A | Photographic material containing sulphonic acid group containing disazo dyestuffs | CIBA-GEIGY AG (CH) | 1978-10-03 | — | — | US | disclosed |
| US-4051123-A | Sulfonic-acid-group containing disazo dyestuffs | CIBA-GEIGY AG (CH) | 1977-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407328-A1 | BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | BRD4, BICRA, BRDT | ALDH1A1 3541/4885DDX3X 1317/4885SMN1; SMN2 4754/4885 |
| US-10738016-B2 | BRD4-kinase inhibitors as cancer therapeutics | BRD4, BICRA, BRDT | ALDH1A1 3541/4885DDX3X 1317/4885SMN1; SMN2 4754/4885 |
| US-20070287195-A1 | Carohydrate-Ligand Conjugates and Their Application for the Analysis of Carbohydrate-Protein Interaction | CA11, CNPY3, CACYBP | ALDH1A1 3453/4885DDX3X 3879/4885SMN1; SMN2 3837/4885 |
| US-20190055203-A1 | POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | BRD4, BICRA, BRDT | ALDH1A1 3241/4885DDX3X 1399/4885SMN1; SMN2 4058/4885 |
| US-11643396-B2 | BRD4-kinase inhibitors as cancer therapeutics | BRD4, BICRA, BRDT | ALDH1A1 3541/4885DDX3X 1317/4885SMN1; SMN2 4754/4885 |
| US-20170226065-A1 | POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | BRD4, BICRA, BRDT | ALDH1A1 3241/4885DDX3X 1399/4885SMN1; SMN2 4058/4885 |
| US-20070015759-A1 | Metasubstituted thiazolidinones, their manufacture and use as a drug | PLK4, PDXK, PLK2 | ALDH1A1 997/4885DDX3X 3444/4885SMN1; SMN2 3196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.